Ezetimibe final guidance [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2019-09-30 15:33 (965 d 18:46 ago) – Posting: # 20658
Views: 3,389

Dear Ohlbe,

I agree with your points about error, etc.

» But if you directly measure total (after deconjugation), and then calculate the glucuronide by substracting unconjugated from total, you won't have this problem. The increased error will affect the glucuronide, but you don't use these concentrations for the determination of bioequivalence.
»
» Wouldn't this be acceptable ?

I don’t know what is acceptable for the agencies. For me, absolutely. I still don’t get the point why one has to present the aglycone at all. Heck, it is not used in the BE assessment.

Dif-tor heh smusma 🖖 [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,091 posts in 4,630 threads, 1,566 registered users;
online 47 (1 registered, 46 guests [including 43 identified bots]).
Forum time: Monday 10:19 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5